We are live on ! Find out more
SFM

Sphera Funds Management Portfolio holdings

AUM $630M
1-Year Est. Return 108.65%
This Fund
S&P 500
This Quarter Est. Return
+30.64%
1 Year Est. Return
+108.65%
3 Year Est. Return
+217.64%
5 Year Est. Return
+342.91%
10 Year Est. Return
+2,254.45%
AUM
$1.06B
AUM Growth
+$264M
Cap. Flow
+$103M
Cap. Flow %
9.71%
Top 10 Hldgs %
50.25%
Holding
118
New
40
Increased
18
Reduced
23
Closed
31

Top Buys

Rank Stock Value
1
ABBV icon
AbbVie
ABBV
+$50.2M
2
NICE icon
Nice
NICE
+$22.7M
3
AMGN icon
Amgen
AMGN
+$18.3M
4
AZN icon
AstraZeneca
AZN
+$16.5M
5
LLY icon
Eli Lilly
LLY
+$13.8M

Top Sells

Rank Stock Value
1
ALXN
Alexion Pharmaceuticals
ALXN
+$22.4M
2
PFE icon
Pfizer
PFE
+$19.7M
3
SRPT icon
Sarepta Therapeutics
SRPT
+$18.3M
4
NVO
Novo Nordisk
NVO
+$11.2M
5
XLP icon
State Street Consumer Staples Select Sector SPDR ETF
XLP
+$7.91M

Sector Composition

Rank Sector Weight
1 Healthcare 64.11%
2 Technology 8.21%
3 Consumer Discretionary 1.63%
4 Industrials 1.41%
5 Communication Services 1.16%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
SNDX icon
76
CALL
Syndax Pharmaceuticals
SNDX
$1.69B
$1.48M 0.14%
+100,000
New +$1.52M
VKTX icon
77
Viking Therapeutics
VKTX
$3.7B
$1.48M 0.14%
205,000
-385,000
-65% -$2.56M
NBSE
78
DELISTED
NeuBase Therapeutics, Inc. Common Stock
NBSE
$1.32M 0.12%
+7,500
New +$1.26M
IMUX icon
79
Immunic
IMUX
$190M
$1.21M 0.11%
+10,000
New +$1.02M
ISEE
80
DELISTED
IVERIC bio, Inc. Common Stock
ISEE
$1.02M 0.1%
200,000
+76,576
+62% +$319K
BLU
81
DELISTED
BELLUS Health Inc.
BLU
$1.01M 0.09%
+97,805
New +$991K
NEOS
82
DELISTED
Neos Therapeutics, Inc
NEOS
$651K 0.06%
950,311
-1,559,157
-62% -$1.24M
CAMT icon
83
Camtek
CAMT
$6.18B
$468K 0.04%
+37,184
New +$423K
TCRR
84
DELISTED
TCR2 Therapeutics Inc. Common Stock
TCRR
$461K 0.04%
+30,000
New +$346K
CLRB icon
85
Cellectar Biosciences
CLRB
$20.5M
$112K 0.01%
292
– –
OTLKW
86
DELISTED
Outlook Therapeutics, Inc. Series A Warrant Expiring 02/18/2022
OTLKW
$33K ﹤0.01%
129,500
– –
ACAD icon
87
Acadia Pharmaceuticals
ACAD
$4.43B
– –
-157,000
Closed -$6.63M
ALDX icon
88
Aldeyra Therapeutics
ALDX
$92.9M
– –
-1,069,089
Closed -$2.64M
APLT
89
DELISTED
Applied Therapeutics
APLT
– –
-67,967
Closed -$2.22M
ARVN icon
90
Arvinas
ARVN
$518M
– –
-145,781
Closed -$5.88M
AUDC icon
91
AudioCodes
AUDC
$244M
– –
-206,619
Closed -$4.94M
BEAM icon
92
Beam Therapeutics
BEAM
$2.63B
– –
-264,681
Closed -$4.76M
BPMC
93
DELISTED
Blueprint Medicines
BPMC
– –
-109,500
Closed -$6.4M
CRM icon
94
Salesforce
CRM
$151B
– –
-35,529
Closed -$5.12M
CYCN icon
95
Cyclerion Therapeutics
CYCN
$14.9M
– –
-6,249
Closed -$331K
DTIL icon
96
Precision BioSciences
DTIL
$180M
– –
-4,912
Closed -$889K
EOLS icon
97
Evolus
EOLS
$385M
– –
-550,000
Closed -$2.28M
IWM icon
98
PUT
iShares Russell 2000 ETF
IWM
$79.8B
– –
-900,000
Closed -$103M
MIST icon
99
Milestone Pharmaceuticals
MIST
$138M
– –
-67,992
Closed -$125K
NERV icon
100
Minerva Neurosciences
NERV
$185M
– –
-21,045
Closed -$1.01M
1 2 3
4
5

Similar funds

VIM
Vancity Investment Management Vancouver, British Columbia, Canada $629M AUM 2.49% 1-Year Est. Return
KCMH
Keywise Capital Management (HK) Hong Kong $630M AUM 81.01% 1-Year Est. Return
FCFC
First Commonwealth Financial Corp Indiana, Pennsylvania $629M AUM 20.47% 1-Year Est. Return
BI
BlueSpruce Investments Chicago, Illinois $631M AUM 11.83% 1-Year Est. Return
PWW
Pettyjohn Wood & White Lynchburg, Virginia $628M AUM 20.96% 1-Year Est. Return
TTSTC
Texas Treasury Safekeeping Trust Company Austin, Texas $628M AUM 15.58% 1-Year Est. Return
SWP
Summit Wealth Partners Orlando, Florida $632M AUM 9.71% 1-Year Est. Return
EIM
Essex Investment Management Boston, Massachusetts $632M AUM 95.36% 1-Year Est. Return

Sphera Funds Management's Q2 2020 Portfolio in Review

As of Q2 2020, Sphera Funds Management held 118 positions worth $1.06B, up 33% from $800M the previous quarter. Its ten largest holdings account for 50% of the portfolio.

Sphera Funds Management deployed $103M of net new capital in Q2 2020, opening 40 new positions and adding to 18 existing holdings. Its largest new stake was Nice: 129,406 shares worth $24.5M.

By sector, the portfolio is most concentrated in Healthcare at 64% of assets, down from 66% a quarter earlier, followed by Technology and Consumer Discretionary.

On the sell side, the largest reduction was Sarepta Therapeutics, an estimated $18.3M trimmed.

  • Sphera Funds Management's largest Q2 2020 buy was Nice: 129,406 shares worth $24.5M.
  • Sphera Funds Management added most to AbbVie in Q2 2020, an estimated $50.2M increase.
  • Sphera Funds Management's biggest Q2 2020 reduction was Sarepta Therapeutics, cutting an estimated $18.3M.
  • Sphera Funds Management fully exited Alexion Pharmaceuticals in Q2 2020, selling an estimated $22.4M.
  • Sphera Funds Management's ten largest holdings make up 50% of its $1.06B portfolio in Q2 2020.
  • Sphera Funds Management opened 40 new positions and closed 31 in Q2 2020.
  • Sphera Funds Management's portfolio value rose 33% quarter-over-quarter to $1.06B.

Based on Sphera Funds Management's 13F filing for Q2 2020, filed 13 Aug 2020.